Evidence map›Paper›PMID 42373605›Full record

ArticleBlood cancer journal2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Tulika Rudra Gupta, Jessica M Stempel, Najla H Al Ali, Amy E DeZern, Mikkael A Sekeres, Geoffrey L Uy and 49 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

59 authors.

Jan Philipp Bewersdorf *Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-3352-0902
Tariq Kewan *Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4651-5125
Luca Lanino *Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2404-8829
Wei WeiDepartment of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Tulika Rudra GuptaDepartment of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0009-0005-7089-2643
Jessica M StempelSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
Najla H Al AliDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Amy E DeZernSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5225-4609
Mikkael A SekeresSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Geoffrey L UyWashington University School of Medicine, Saint Louis, MO, USA.
Samuel UrrutiaWashington University School of Medicine, Saint Louis, MO, USA.
Hetty E CarrawayDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-5241-3614
Pinkal DesaiWeill Cornell Medicine, New York City, NY, USA.
Elizabeth A GriffithsRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-0288-8248
Eytan M SteinDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew M BrunnerDivision of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Christine McMahonUniversity of Colorado, Aurora, CO, USA.
Rory M ShallisDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Joshua F ZeidnerUniversity of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-9014-1514
Michael R SavonaVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Hayley HawkinsVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Namrata Sonia ChandhokSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Constantine N LogothetisWashington University School of Medicine, Saint Louis, MO, USA.
Aram BidikianSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
Ted M GetzSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
Gail J RobozWeill Cornell Medicine, New York City, NY, USA.
Benjamin RollesSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-7393-861X
Eunice S WangRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-8644-0968
Amyah C HarrisDivision of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Maria L AmayaUniversity of Colorado, Aurora, CO, USA.ORCID http://orcid.org/0000-0001-9503-5019
Somedeb BallVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Justin GrenetWeill Cornell Medicine, New York City, NY, USA.
Zhuoer XieDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-1266-9804
Yazan F MadanatHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-9573-2690
Yasmin AbazaNorthwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-9156-7912
Talha BadarDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0003-1548-918X
Jaclynn CamposDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Jaroslaw P MaciejewskiDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland, OH, USA.
David SallmanDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-0504-8233
Anoop EnjetiDepartment of Haematology, Calvary Mater Hospital, Newcastle, NSW, Australia.ORCID http://orcid.org/0000-0001-8069-090X
Kamal Al-RabiKing Hussein Cancer Center, Amman, Jordan.
Khalid HalahlehKing Hussein Cancer Center, Amman, Jordan.ORCID http://orcid.org/0000-0002-1161-9138
Devendra HiwaseDepartment of Haematology, The Royal Adelaide Hospital, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-6666-3056
Maria Diez-CampeloHematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain.ORCID http://orcid.org/0000-0002-1467-6779
David ValcarcelDepartment of Hematology and Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8747-078X
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-6333-5049
Lisa Pleyer3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Ioannis KotsianidisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.ORCID http://orcid.org/0000-0001-7668-0186
Vassiliki PappaHematology Division, Second Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0003-0421-9424
Valeria SantiniMDS Unit, Hematology, AOU Careggi-Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-5439-2172
Angela ConsagraMDS Unit, Hematology, AOU Careggi-Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Aref Al-KaliMayo Clinic, Rochester, MN, USA.
Seishi OgawaDepartment of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-7778-5374
Yasuhito NannyaInstitute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6526-0992
Maximilian StahlSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
Matteo Giovanni Della PortaIRCCS Humanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Rami S KomrokjiDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-1876-5269
Amer M ZeidanSection of Medical Oncology and Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.ORCID http://orcid.org/0000-0001-7017-8160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated. We analyzed 1907 patients with HR-MDS from 31 centers in 9 countries who were treated with HMA monotherapy or HMA/VEN in the frontline setting (HMA monotherapy: n = 1773; HMA/VEN: n = 134). Responses were assessed centrally by two investigators using the IWG 2023 response criteria. Addition of VEN improved composite complete remission (cCR) rates (48.8% vs. 27.7%; p < 0.001) but not CR rates (17.1% vs. 11.7%; p = 0.16). In multivariable logistic regression analysis, cCR remained favorable for HMA/VEN vs. HMA monotherapy (Odds Ratio [OR]: 2.49; 95% CI: 1.56-3.96; p < 0.001). However, we did not observe a statistically significant difference in OS for HMA/VEN vs. HMA monotherapy (Hazard Ratio [HR]: 0.83; 95% CI: 0.64-1.07; p = 0.15). In subgroup analyses, patients with TP53 wild-type disease (HR: 0.47; 95% CI: 0.29-0.74; p = 0.002) had a significant improvement in OS and those with ≥10% bone marrow blasts (HR: 0.73; 95% CI: 0.53-1.01; p = 0.06) had a trend towards OS benefit with HMA/VEN.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicMyelodysplastic SyndromesSulfonamidesAdultAgedAged, 80 and overAzacitidineDatabases, FactualDNA MethylationFemaleHumansMaleMiddle AgedTreatment OutcomeAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Identifiers

PMID42373605
PMCPMC13575243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.